The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
The new sterile filling line meets cGMP aseptic filling regulatory requirements
APAC to see a reduction in imported surgical robotics
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Subscribe To Our Newsletter & Stay Updated
